DK3114215T3 - Grupperede nk-celler fra navlestrengsblod og anvendelse deraf til behandling af cancer og kronisk infektionssygdom - Google Patents

Grupperede nk-celler fra navlestrengsblod og anvendelse deraf til behandling af cancer og kronisk infektionssygdom Download PDF

Info

Publication number
DK3114215T3
DK3114215T3 DK15709149.7T DK15709149T DK3114215T3 DK 3114215 T3 DK3114215 T3 DK 3114215T3 DK 15709149 T DK15709149 T DK 15709149T DK 3114215 T3 DK3114215 T3 DK 3114215T3
Authority
DK
Denmark
Prior art keywords
grouped
cancer
cells
treatment
umbilical cord
Prior art date
Application number
DK15709149.7T
Other languages
Danish (da)
English (en)
Inventor
Gonzalez Martin Villalba
Zhao Yang Lu
Patrick Henno
Jean-François Rossi
Original Assignee
Emercell Sas
Inst Nat Sante Rech Med
Ct Hospitalier Universitaire Montpellier
Univ Montpellier
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Emercell Sas, Inst Nat Sante Rech Med, Ct Hospitalier Universitaire Montpellier, Univ Montpellier filed Critical Emercell Sas
Application granted granted Critical
Publication of DK3114215T3 publication Critical patent/DK3114215T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0646—Natural killers cells [NK], NKT cells
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
    • A01N1/00—Preservation of bodies of humans or animals, or parts thereof
    • A01N1/10—Preservation of living parts
    • A01N1/14—Mechanical aspects of preservation; Apparatus or containers therefor
    • A01N1/146—Non-refrigerated containers specially adapted for transporting or storing living parts whilst preserving
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/15—Natural-killer [NK] cells; Natural-killer T [NKT] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/0081—Purging biological preparations of unwanted cells
    • C12N5/0087—Purging against subsets of blood cells, e.g. purging alloreactive T cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
    • C12N5/0662—Stem cells
    • C12N5/0665—Blood-borne mesenchymal stem cells, e.g. from umbilical cord blood
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C12N2501/2302—Interleukin-2 (IL-2)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C12N2501/2315—Interleukin-15 (IL-15)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Cell Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Rheumatology (AREA)
  • Oncology (AREA)
  • Dentistry (AREA)
  • Environmental Sciences (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Virology (AREA)
DK15709149.7T 2014-03-07 2015-03-09 Grupperede nk-celler fra navlestrengsblod og anvendelse deraf til behandling af cancer og kronisk infektionssygdom DK3114215T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP14305332 2014-03-07
PCT/EP2015/054837 WO2015132415A1 (en) 2014-03-07 2015-03-09 Pooled nk cells from ombilical cord blood and their uses for the treatment of cancer and chronic infectious disease

Publications (1)

Publication Number Publication Date
DK3114215T3 true DK3114215T3 (da) 2021-06-21

Family

ID=50277168

Family Applications (1)

Application Number Title Priority Date Filing Date
DK15709149.7T DK3114215T3 (da) 2014-03-07 2015-03-09 Grupperede nk-celler fra navlestrengsblod og anvendelse deraf til behandling af cancer og kronisk infektionssygdom

Country Status (8)

Country Link
US (1) US20170073637A1 (enExample)
EP (1) EP3114215B1 (enExample)
JP (2) JP6775426B2 (enExample)
CN (1) CN106164256B (enExample)
CA (1) CA2941519C (enExample)
DK (1) DK3114215T3 (enExample)
ES (1) ES2880718T3 (enExample)
WO (1) WO2015132415A1 (enExample)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017042393A1 (en) * 2015-09-11 2017-03-16 Emercell Sas Pooled nk cells from umbilical cord blood associated with antibodies and their uses for the treatment of disease
KR20180086204A (ko) * 2015-11-05 2018-07-30 글리코스템 떼라퓨틱스 비.브이. 면역치료법에 사용하기 위한 조성물
WO2017136818A2 (en) * 2016-02-05 2017-08-10 Washington University Compositions and methods for targeted cytokine delivery
EP3746095A4 (en) 2018-02-01 2021-04-21 Nkmax Co., Ltd. Method of producing natural killer cells and composition for treating cancer
JP7273421B2 (ja) 2018-02-21 2023-05-15 ボード オブ リージェンツ，ザ ユニバーシティ オブ テキサス システム ナチュラルキラー細胞の活性化および拡大のための方法ならびにその使用
BR112020016876A2 (pt) * 2018-02-21 2020-12-15 Board Of Regents, The University Of Texas System Células apresentadoras de antígeno universal e usos das mesmas
JP2021534779A (ja) 2018-08-27 2021-12-16 アフィメッド ゲゼルシャフト ミット ベシュレンクテル ハフツンク 抗体構築物がプレロードされた凍結保存ｎｋ細胞
JP6838750B2 (ja) * 2019-01-21 2021-03-03 株式会社ガイアバイオメディシン Ｎｋ細胞を含む細胞集団の製造方法
WO2020152661A1 (ja) * 2019-01-21 2020-07-30 株式会社ガイアバイオメディシン Ｎｋ細胞を含む細胞集団の製造方法
JP6977969B2 (ja) * 2019-03-22 2021-12-08 株式会社ガイアバイオメディシン 免疫細胞提供システム
JP2021035400A (ja) * 2020-12-07 2021-03-04 株式会社ガイアバイオメディシン Ｎｋ細胞を含む細胞集団の製造方法

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101077912B1 (ko) * 2008-10-24 2011-10-31 주식회사 메디셀 제대혈로부터 효율적인 자연살해세포의 증식 및 분화 방법
CA2703428A1 (en) * 2010-05-11 2011-11-11 Mcgill University Health Center Pooled cord blood units
JP5996533B2 (ja) * 2010-07-13 2016-09-21 アントフロゲネシス コーポレーション ナチュラルキラー細胞を生成させる方法
KR101447546B1 (ko) * 2011-03-03 2014-10-08 한국생명공학연구원 제대혈 ｃｄ14 양성 단핵세포로부터 자연살해세포 분화 및 증식 방법
WO2012146702A1 (en) * 2011-04-28 2012-11-01 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for preparing accessory cells and uses thereof for preparing activated nk cells
JP5840876B2 (ja) * 2011-06-24 2016-01-06 テラ株式会社 Ｎｋ細胞を増幅するための組成物及び方法
JP5572863B2 (ja) * 2011-06-24 2014-08-20 国立大学法人九州大学 Ｎｋ細胞の増幅方法
CN115137753A (zh) * 2013-02-05 2022-10-04 细胞结构公司 来自胎盘的自然杀伤细胞

Also Published As

Publication number Publication date
EP3114215B1 (en) 2021-04-14
EP3114215A1 (en) 2017-01-11
ES2880718T3 (es) 2021-11-25
CA2941519C (en) 2022-09-06
JP2020114248A (ja) 2020-07-30
CA2941519A1 (en) 2015-09-11
CN106164256B (zh) 2021-08-10
CN106164256A (zh) 2016-11-23
JP2017508479A (ja) 2017-03-30
JP6775426B2 (ja) 2020-10-28
US20170073637A1 (en) 2017-03-16
WO2015132415A1 (en) 2015-09-11

Similar Documents

Publication Publication Date Title
IL285965B (en) Ex vivo organ care system
IL296080B1 (en) Method for treating cancer
DK3114215T3 (da) Grupperede nk-celler fra navlestrengsblod og anvendelse deraf til behandling af cancer og kronisk infektionssygdom
IL290993A (en) Methods of diagnosing and treating tourette syndrome
IL280899A (en) Heterocyclic compounds for cancer imaging and treatment and methods for their use
DK3202305T3 (da) Engangsendoskop og system
EP3600509A4 (en) Patient interface
IL255261A0 (en) Methods for treating cancer
DK3191020T3 (da) Medicinsk/kirurgisk implantat
EP3448485A4 (en) PATIENT INTERFACE
EP3601536A4 (en) TREATMENT PROCESSES
LT3277842T (lt) Vėžio pacientų gydymo būdai farneziltransferazės inhibitoriais
DK3757206T3 (da) Transduktionsfremgangsmåde og cellebehandling
DK3590543T3 (da) Medicinsk forbinding
EP3522966A4 (en) PATIENT INTERFACES
BR112016030398A2 (pt) Instrumento cirúrgico endoscópico
DK3197354T3 (da) Medicinsk anordning
DK3240612T3 (da) Fremgangsmåder til behandling af nethindesygdomme
IL247111A0 (en) Preventive or therapeutic agent for kidney disease
PL3186244T3 (pl) Analogi dioksolanowe urydyny w leczeniu raka
HUE050944T2 (hu) Kezelési eljárás tradipitant alkalmazásával
EP3445431A4 (en) PATIENT INTERFACE AND ASPECTS THEREOF
IL256103B (en) Compositions and methods for treating celiac sprue disease
DK3678714T3 (da) Vævsmanipuleret medicinsk indretning
IL251903A0 (en) Apilimod for use in the treatment of colorectal cancer